{"preliminary_commentary":{"by_channel":{"x_thread":4,"youtube":2,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03340129\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["nivolumab","ipilimumab","stereotactic radiotherapy"]],"indication":"melanoma brain metastases","name":"ABC-X","nct_id":"NCT03340129","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=abc-x-nct03340129. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ABC-X","arms":[{"description":"Nivolumab 1mg/kg and ipilimumab 3mg/kg Q3W x 4 doses, then nivolumab 480 mg every 4 weeks.\n\nAny form of salvage therapy (surgery or radiotherapy) may be administered to either cohort for the treatment of intracranial disease progression.","label":"Nivolumab + ipilimumab","type":"ACTIVE_COMPARATOR"},{"description":"Nivolumab 1mg/kg and ipilimumab 3mg/kg Q3W x 4 doses, then nivolumab 480 mg every 4 weeks.\n\nStereotactic radiotherapy 16 to 22 Gy in 1 fraction or 24 to 30 Gy, hypofractionated for larger lesions. Stereotactic radiotherapy to commence within 7 days of of the baseline / planning MRI brain. Hypofractionated stereotactic radiotherapy should be completed within 14 day of the first fraction.\n\nAny form of salvage therapy (surgery or radiotherapy) may be administered to either cohort for the treatment of intracranial disease progression.","label":"Nivolumab + ipilimumab,concurrent SRS","type":"ACTIVE_COMPARATOR"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2029-08","type":"ESTIMATED"},"conditions":["Melanoma Stage Iv"],"enrollment":{"count":218,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ipilimumab","otherNames":["Yervoy"],"type":"DRUG"},{"name":"Nivolumab","otherNames":["Opdivo"],"type":"DRUG"},{"name":"Stereotactic Radiotherapy","otherNames":[],"type":"RADIATION"},{"name":"Salvage therapy","otherNames":[],"type":"OTHER"}],"last_update":"2026-10-08","lead_sponsor":"Melanoma Institute Australia","official_title":"A Phase II, Open Label, Randomised, Controlled Trial of Ipilimumab and Nivolumab With Concurrent Intracranial Stereotactic Radiotherapy Versus Ipilimumab and Nivolumab Alone in Patients With Melanoma Brain Metastases.","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Neurological specific cause of death","timeFrame":"One year"}],"references":[{"citation":"Phillips WJ, Baghai T, Ong M, Lo B, Ibrahim AM, Smith TKT, Song X. A Contemporary Report of Clinical Outcomes in Patients with Melanoma Brain Metastases. Curr Oncol. 2021 Jan 13;28(1):428-439. doi: 10.3390/curroncol28010045.","pmid":"33450821","type":"DERIVED"}],"start_date":{"date":"2019-08-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)","url":"https://clinicaltrials.gov/study/NCT03340129"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/abc-x-nct03340129"}